Indivior Dividends - INDV

Indivior Dividends - INDV

[ADVERT]
Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type
Indivior Plc INDV London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
4.40 2.1% 214.20 16:35:27
Open Price Low Price High Price Close Price Previous Close
212.40 208.00 215.40 214.20 209.80
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Indivior INDV Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
18/02/2016FinalUSX9.531/12/201431/12/201516/06/201617/06/201629/07/201612.7
05/08/2015InterimUSX3.230/12/201430/06/201517/09/201518/09/201523/10/20150

Top Dividend Posts

DateSubject
20/9/2021
18:31
waldron: [United Kingdom] INDIVIOR PLC (INDV) Delayed Quote. Delayed London Stock Exchange - 09/20 11:35:14 am 209.8 GBX +1.06% Possible strong resistence at 220p Https://www.marketscreener.com/INDIVIOR-19344116/
03/9/2021
17:39
adrian j boris: [United Kingdom] INDIVIOR PLC (INDV) Delayed Quote. Delayed London Stock Exchange - 09/03 04:35:11 pm 198.9 GBX -1.44% If trend up continues next resistence might well be 217.40p
31/8/2021
21:54
waldron: EXTREME BROKER TARGETS Numis Buy - 320.00p THE WISH LIST GIVING BOXES,Supports and Resistences to determine channels and trends together with broker targets which might of course make you smile or and smirk 140 to 150p 150 to 160p 160 to 170p 170 to 180p 180 to 190p 190 to 200p$$$$$$$$$$$$ WE ARE HERE $$$$$$$$$$$$$$$ 200 to 220pJefferies target 220p Https://www.marketscreener.com/INDIVIOR-19344116/ DECEMBER END 2019 GIVES 39p December 2020 ends at 108.80p January 2021 ends at 137.35p February 2021 ends at 128.10p March 2021 ends at 127.10p April 2021 ends at 152.60p May 2021 ends at 156.40p June 2021 ends at 155.80p July 2021 ends at 165p August 2021 wnds at 194.40p Http://indivior.com/ Https://www.londonstockexchange.com/exchange/prices-and-markets/stocks/summary/company-summary/GB00BRS65X63GBGBXSSMM.html?lang=en INVVY ADR USD EQUAL TO 5 INDV SHARES Https://www.marketscreener.com/INDIVIOR-PLC-19356217/ Upcoming events on INDIVIOR PLC November/04/2021 Q3 2021 Earnings Release (Projected)
30/7/2021
19:30
waldron: THE WISH LIST GIVING BOXES,Supports and Resistences to determine channels and trends together with broker targets which might of course make you smile or and smirk 100 to 110p 110 to 120p 120 to 130p 130 to 140p 140 to 150p 150 to 160p 160 to 170p$$$$$$$$$$$$ WE ARE HERE $$$$$$$$$$$$$$$ 170 to 180p 180 to 190p 190 to 200p 200 to 220pJefferies target 220p Https://www.marketscreener.com/INDIVIOR-19344116/ DECEMBER END 2019 GIVES 39p December 2020 ends at 108.80p January 2021 ends at 137.35p February 2021 ends at 128.10p March 2021 ends at 127.10p April 2021 ends at 152.60p May 2021 ends at 156.40p June 2021 ends at 155.80p July 2021 ends at 165p Http://indivior.com/ Https://www.londonstockexchange.com/exchange/prices-and-markets/stocks/summary/company-summary/GB00BRS65X63GBGBXSSMM.html?lang=en INVVY ADR USD EQUAL TO 5 INDV SHARES Https://www.marketscreener.com/INDIVIOR-PLC-19356217/ Upcoming events on INDIVIOR PLC November/04/2021 Q3 2021 Earnings Release (Projected)
30/7/2021
10:33
waldron: 30 July 2021 Indivior Announces Share Repurchase Program Details Slough, UK and Richmond, VA, July 30, 2021 - Indivior PLC (LON: INDV) today announced that, as outlined in its half-year results on 29 July 2021, it will commence a share repurchase program of Indivior's ordinary shares of $0.10 each (the "Ordinary Shares") for up to a maximum consideration of $100 million (the "Program").
15/7/2021
11:56
waldron: 14 July 2021 Indivior to Announce Q2 / H1 2021 Results and Host a Presentation on July 29(th) Slough, UK, and Richmond, VA, July 14, 2021 - Indivior PLC (LON: INDV) today announced that it will release its Q2 / H1 2021 results on July 29(th) at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com . Mark Crossley, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 13:00 GMT (8:00 a.m. U.S. Eastern) on July 29(th) . Access to the Live Webcast Presentation The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. The webcast link is Https://edge.media-server.com/mmc/p/s3gpwt3q .
25/5/2021
20:48
sarkasm: 25 May 2021 Indivior to Participate in Jefferies Virtual Healthcare Conference Slough, UK and Richmond, VA - May 25, 2021 - Indivior PLC (LON: INDV) today announced that Mark Crossley, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will participate in the Jefferies Virtual Healthcare Conference. Mark Crossley will present on June 1, 2021, at 10:30 AM (ET). The live presentation will be available on Indivior's website www.indivior.com and can also be viewed using the following webcast link: hxxps://wsw.com/webcast/jeff174/indv.l/2076381 . About Indivior Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. Our vision is for all patients around the world to have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. The name is the fusion of the words individual and endeavor, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior . Contact : Jason Thompson 804-402-7123 Vice President, Investor Relations jason.thompson@indivior.com
18/1/2021
19:19
timmy11: RE: Interesting analysis of Indivior (Litigation Investor)Today 14:44 This Report is excellent, very comprehensive & well worth the read. Some of the points it makes are as follows: "Suboxone sales have remained resilient in the face of generic competition (and even saw modest growth in the most recent quarter, Q3 2020) Sublocade unit growth is accelerating (growing 15% in Q3 2020 over Q2 2020) Sublocade sales should easily exceed management guidance A competitive entrant, Brixadi, has been delayed (likely, >12 months) as Braeburn (Brixadi's license holder in the U.S.) received a complete response letter from the FDA. Based on our projections for Sublocade sales growth it is easy to see a near term value for Indivior ordinary shares of 200p." It also states that the Reckitt claim is a " baseless preliminary claim filed by Indivior’s former parent company" that is "procedurally defective and substantively precluded due to Reckitt’s alleged acts of fraud or dishonesty." I agree with the Report and believe that the Reckitt claim was a crude attempt to try & stifle a much stronger claim by INDV on Reckitt. This is also the view taken by the Report. It goes on to forecast an share price of £5 for INDV by 2025 based on INDV's market leading position and on the growth of SUBLOCADE as well as other products supplied by INDV using their monthly injectable technology such as PERSERIS designed to combat Schizophrenia. INDV's share price should continue to firm from here on the run-up to releasing its full year results on 18th February.
15/1/2021
17:52
grupo guitarlumber: Indivior is the biggest FTSE 250 gainer today. Would I buy it now? Manika Premsingh | Friday, 15th January, 2021 Business development to success and FTSE 100 250 350 growth concept. The FTSE 250 opioid addiction treatment provider Indivior (LSE: INDV) is the biggest index gainer today as I write. Its share price is up 9%, continuing its recovery after a sharp fall in late November. Why the share price rose INDV’s better-than-expected financial results are the clear reason for the uptick in share price. It now expects revenue to be at least $25m higher than it had expected earlier for the full year. It also expects expenses to be lower, resulting in an improved income forecast. What’s next for the INDV share price I reckon that the latest news will provide continued impetus for INDV’s share price. It’s now at 115p, up from the sub-100p levels it was at before the last week of December. The big decline started in late November, when it crashed 30% in a day following news that its former parent company — Reckitt Benckiser — had filed a £1bn claim on it. Even now the share price is still much lower than its 131p levels at the time. But at least it’s now closer than ever to getting back there. When I last wrote about Indivior, after its share price fall, my sense was that its share price would be dependent more on its own performance than anything else. If the share price reaction to its latest results is anything to go by, it only proves the point I was making at the time. If its performance remains consistent, I reckon that its share price can climb up further. This is especially so in today’s bullish market, where investors are rewarding companies that are performing well. Battling the opioid crisis Moreover, the seriousness of the opioid crisis is big and rising, an issue that Indivior is well placed to address. According to the World Health Organisation, globally 0.5m deaths are caused by drug use every year, of which 70% are opioid-related. Moreover, between 2010 and 2018, the number of people dying of opioid overdose in the US increased by 120%. Past problems still haunt Despite this, as an investor I’m cautious because of INDV’s problems from the recent past, which include accusations of mis-selling and resulted in its former CEO being imprisoned. Almost two months after I wrote about INDV, it indeed appears to have put the episode behind it. It has also said that Reckitt Benckiser’s claim is without merit. Further, its financials had suffered quite the blow in the first nine months of 2020, with a sharp decline in revenue. The latest numbers, then, are a surprise development and not one that reflects the inherent, ongoing strength of the company. I think the INDV stock looks much better after its results than it did two months ago when it was far more in the thick of a crisis. It could continue to see improvements from here. But I really want to see some more predictability to its financials before buying the stock. Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned.
10/11/2020
19:02
waldron: Indivior to Participate in Upcoming Conferences Tue, 10th Nov 2020 07:00 RNS Number : 7452E Indivior PLC 10 November 2020 Indivior Announces Participation in Upcoming Investor Conferences Slough, United Kingdom and Richmond, Virginia - November 10, 2020 - Indivior PLC (LON: INDV) today announced its participation in the following upcoming investor conferences: · November 16th, 8:00 AM US Eastern Time (ET): Stifel Virtual Healthcare Conference (link). · November 17th, 12:00 PM US Eastern Time (ET): Jefferies Virtual Global Healthcare Conference (link). About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior. For Further Information Investor Enquiries Jason Thompson VP, Investor Relations Indivior PLC +1 804 402 7123 jason.thompson@indivior.com Media Enquiries Jonathan Sibun Tulchan Communications US Media Inquiries +44 207 353 4200 +1 804 594 0836 Indiviormediacontacts@indivior.com -ends-
ADVFN Advertorial
Your Recent History
LSE
INDV
Indivior
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210921 21:41:56